Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H13N3O3S |
Molecular Weight | 267.304 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
InChI
InChIKey=NHUHCSRWZMLRLA-UHFFFAOYSA-N
InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7Curator's Comment: description was created based on several sources, including
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7
Curator's Comment: description was created based on several sources, including
Sulfisoxazole is a sulfonamide antibacterial antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfisoxazole acetyl in combination with erythromycin ethylsuccinate is used for treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae. Sulfisoxazole acetyl is a prodrug of sulfisoxazole. Acetyl group is added to make the drug poorly water soluble, and is hydrolyzed in vivo to the active drug. Sulfisoxazole and its acetylated metabolites are excreted primarily by the kidneys through glomerular filtration. Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7486915 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL Approved UseFor treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae. Launch Date5.8000317E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
111.85 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3907496 |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFISOXAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
874.15 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3907496 |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFISOXAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3907496 |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFISOXAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
2 g single, intramuscular |
healthy, 29-45 years n = 7 Health Status: healthy Age Group: 29-45 years Sex: M Population Size: 7 Sources: |
|
2 g single, intravenous |
healthy, 29-45 years n = 7 Health Status: healthy Age Group: 29-45 years Sex: M Population Size: 7 Sources: |
|
2 g single, oral |
healthy, 29-45 years n = 7 Health Status: healthy Age Group: 29-45 years Sex: M Population Size: 7 Sources: |
|
4 g 1 times / day multiple, oral Dose: 4 g, 1 times / day Route: oral Route: multiple Dose: 4 g, 1 times / day Sources: |
unhealthy, 74 years n = 1 Health Status: unhealthy Age Group: 74 years Sex: M Population Size: 1 Sources: |
Disc. AE: Granulocytopenia... AEs leading to discontinuation/dose reduction: Granulocytopenia Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Granulocytopenia | Disc. AE | 4 g 1 times / day multiple, oral Dose: 4 g, 1 times / day Route: oral Route: multiple Dose: 4 g, 1 times / day Sources: |
unhealthy, 74 years n = 1 Health Status: unhealthy Age Group: 74 years Sex: M Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/18505790/ |
weak | |||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Macrolide-antifol synergism in anti-Pneumocystis carinii therapeutics. | 1991 Nov-Dec |
|
Quantitative determination of sulfonamide in meat by liquid chromatography-electrospray-mass spectrometry. | 2001 Dec 24 |
|
Oxidation of sulfonamide antimicrobials by ferrate(VI) [Fe(VI)O4(2-)]. | 2006 Dec 1 |
|
In-vitro antifungal activities of sulfa drugs against clinical isolates of Aspergillus and Cryptococcus species. | 2007 |
|
Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus. | 2007 Aug |
|
Identification and molecular characterization of Salmonella spp. from unpasteurized orange juices and identification of new serotype Salmonella strain S. enterica serovar Tempe. | 2007 Aug |
|
Pressurized liquid extraction combined with capillary electrophoresis-mass spectrometry as an improved methodology for the determination of sulfonamide residues in meat. | 2007 Aug 3 |
|
The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. | 2007 Jan |
|
Multidrug-resistant Salmonella enterica serotype Typhimurium associated with pet rodents. | 2007 Jan 4 |
|
Simultaneous determination of 17 sulfonamides and the potentiators ormetoprim and trimethoprim in salmon muscle by liquid chromatography with tandem mass spectrometry detection. | 2007 Jan-Feb |
|
Rituals, ceremonies and customs related to sacred trees with a special reference to the Middle East. | 2007 Jul 9 |
|
Antimicrobial susceptibility of Salmonella isolated from various products, from 1999 to 2003. | 2007 Jun |
|
Genotypes, serotypes, and antibiotic resistance profiles of Salmonella isolated from commercial North Carolina turkey farms. | 2007 Jun |
|
[Determination of 12 sulfonamides in cosmetics by ultra performance liquid chromatography]. | 2007 Mar |
|
Comparative investigation of prevalence and antimicrobial resistance of Salmonella between pasture and conventionally reared poultry. | 2007 Mar |
|
Changes in antimicrobial susceptibility in a population of Escherichia coli isolated from feedlot cattle administered ceftiofur crystalline-free acid. | 2007 May |
|
The dominance of pandemic serovars of Vibrio parahaemolyticus in expatriates and sporadic cases of diarrhoea in Thailand, and a new emergent serovar (O3 : K46) with pandemic traits. | 2007 May |
|
Prevalence and antimicrobial resistance of Salmonella recovered from processed poultry. | 2007 Nov |
|
Pharmacokinetic of sulfisoxazole in aqueous humor after topical and subconjunctival application in dogs. | 2007 Nov 15 |
|
A capillary zone electrophoresis method for the quantitative determination of hypoxoside in commercial formulations of African potato (Hypoxis hemerocallidea). | 2007 Nov-Dec |
|
Multiple-locus variable-number tandem repeat analysis of Salmonella Enteritidis isolates from human and non-human sources using a single multiplex PCR. | 2007 Oct |
|
The first case of keratitis caused by Nocardia exalbida. | 2007 Oct |
|
Phenotypic and genotypic antimicrobial resistance patterns of Escherichia coli isolated from dairy cows with mastitis. | 2007 Oct 6 |
|
Probiotic properties of Lactococcus lactis ssp. lactis HV219, isolated from human vaginal secretions. | 2007 Sep |
|
Antimicrobial resistance in generic Escherichia coli isolated from swine fecal samples in 90 Alberta finishing farms. | 2008 |
|
Evaluation of gene expression in a single antibiotic exposure-derived isolate of Salmonella enterica typhimurium 14028 possessing resistance to multiple antibiotics. | 2008 Apr |
|
Antimicrobial resistance and association with class 1 integrons in Escherichia coli isolated from turkey meat products. | 2008 Aug |
|
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. | 2008 Aug |
|
Antimicrobial activity of some sulfonamide derivatives on clinical isolates of Staphylococus aureus. | 2008 Aug 20 |
|
Comparison of antimicrobial resistance in Escherichia coli, Staphylococcus aureus, and Listeria monocytogenes strains isolated from organic and conventional poultry meat. | 2008 Dec |
|
Prevalence and characterization of Salmonella enterica serovar Weltevreden from imported seafood. | 2008 Feb |
|
New Ni(II)-sulfonamide complexes: synthesis, structural characterization and antibacterial properties. X-ray diffraction of [Ni(sulfisoxazole)2(H2O)4].2H2O and [Ni(sulfapyridine)2]. | 2008 Feb |
|
Antimicrobial resistance in Salmonella enterica subspecies enterica serovar Dublin from dairy source calves in the central San Joaquin Valley, California (1998-2002). | 2008 Jul |
|
Safety of raw meat and shellfish in Vietnam: an analysis of Escherichia coli isolations for antibiotic resistance and virulence genes. | 2008 Jun 10 |
|
Integrated food chain surveillance system for Salmonella spp. in Mexico. | 2008 Mar |
|
Contamination of chicken meat with Salmonella enterica Serovar Haardt with nalidixic acid resistance and reduced fluoroquinolone susceptibility. | 2008 Nov |
|
In vitro antimicrobial susceptibility of Streptococcus suis strains isolated from clinically healthy sows in China. | 2008 Oct 15 |
|
Rescue of pulmonary hypertension with an oral sulfonamide antibiotic sulfisoxazole by endothelin receptor antagonistic actions. | 2008 Sep |
|
Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. | 2008 Sep 18 |
|
Multiresidue determination of sulfonamides in chicken meat by polymer monolith microextraction and capillary zone electrophoresis with field-amplified sample stacking. | 2008 Sep 26 |
|
Antimicrobial susceptibility profiles of Salmonella enterica serotypes recovered from pens of commercial feedlot cattle using different types of composite samples. | 2009 Apr |
|
Antimicrobial resistance pattern of Salmonella serotypes isolated from food items and personnel in Addis Ababa, Ethiopia. | 2009 Feb |
|
Condyloma acuminata in child end laser therapy: a case report. | 2009 Feb 4 |
|
Genotype, serotype, and antibiotic resistance of sorbitol-negative Escherichia coli isolates from feedlot cattle. | 2009 Jan |
|
Integron-mediated antibiotic resistance in Shiga toxin-producing Escherichia coli. | 2009 Jan |
|
Standards of medical care in diabetes--2009. | 2009 Jan |
|
Characterization of Salmonella isolates from retail foods based on serotyping, pulse field gel electrophoresis, antibiotic resistance and other phenotypic properties. | 2009 Jan 31 |
|
Associations between reported on-farm antimicrobial use practices and observed antimicrobial resistance in generic fecal Escherichia coli isolated from Alberta finishing swine farms. | 2009 Mar 1 |
|
Changes in antimicrobial resistance among Salmonella enterica subspecies enterica serovar Pullorum isolates in China from 1962 to 2007. | 2009 May 12 |
|
Human metapneumovirus: an emerging respiratory pathogen. | 2010 May |
Patents
Sample Use Guides
Sulfisoxazole acetyl for oral suspension can be calculated based on the sulfisoxazole component (150 mg/kg/day to a maximum of 6 g/day). The total daily dose of sulfisoxazole acetyl for oral suspension should be administered in equally divided doses three or four times a day for 10 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16464516
Curator's Comment: In vitro studies provided support for the protective effect of sulfisoxazole. Here, it was clearly shown that sulfisoxazole attenuated the elevation of nitric oxide (deduced by measuring nitrite) and the reduction in numbers of GABA-containing neurones caused by LPS
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175504
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
WHO-ATC |
S01AB02
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
NDF-RT |
N0000008048
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
NDF-RT |
N0000008048
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
LIVERTOX |
914
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
WHO-VATC |
QS01AB02
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
NDF-RT |
N0000008048
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
NCI_THESAURUS |
C29739
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
WHO-ATC |
J01EB05
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
WHO-VATC |
QJ01EQ05
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
||
|
CFR |
21 CFR 520.2330
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
740T4C525W
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
13120
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
127-69-5
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
102484
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
10207
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | RxNorm | ||
|
m10352
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | Merck Index | ||
|
5344
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
797
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
204-858-9
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
SUB10702MIG
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
683536
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
C47740
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
D013444
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
740T4C525W
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
1638000
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
100000083267
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
CHEMBL453
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
DB00263
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
4177
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
Sulfisoxazole
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
2529
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
DTXSID6021292
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY | |||
|
SULFAFURAZOLE
Created by
admin on Fri Dec 15 15:07:55 UTC 2023 , Edited by admin on Fri Dec 15 15:07:55 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)